SABCS 2022 - DEMONSTRATING CTCs' REAL-TIME IMPACT ON BREAST CANCER TREATMENT Read More
Our Advisors
Enrique Ballesteros MD, Clinical Pathology Advisor
Enrique joined QCDx to offer expert clinical pathology advice in the development of assays for the detection of rare cancer cells with the RareScope technology platform. He is Associate Professor of Pathology and Laboratory Medicine and Chair, Department of Pathology and Laboratory Medicine at UConn Health. Enrique has also been the Medical Director of the Hematopathology service for the past 12 years at UConn Health. He holds an MD from Universidad Javeriana in Bogota, Colombia. He completed his residency in Anatomic & Clinical Pathology at Columbia Presbyterian Medical Center followed by fellowships in Surgical Pathology at Columbia Presbyterian Medical Center and in Hematopathology at Beth Israel Deaconess Medical Center.
Sir Walter Bodmer FRS FRSE, Mentor
Sir Walter is a geneticist with a wide field of study and has made major contributions to the study of the genetics of human populations, gene mapping, and cancer genetics and to our understanding of the human tissue typing system. Early in his career, Walter helped to discover the human leukocyte antigen (HLA) system, vital for the success of organ and bone marrow transplants. He is currently Head of the Cancer and Immunogenetics Laboratory, Cancer and Immunogenetics Lab, MRC Weatherall Institute of Molecular Medicine (WIMM), and Head of the Cancer and Immunogenetics Laboratory, Department of Oncology, University of Oxford. He has been President of the Galton Institute; Chairman and President of the British Association; Chairman of the Leukemia Research Fund's Medical and Scientific Advisory Panel; and Principal of Hertford College, Oxford. He was the first Director General of the Imperial Cancer Research Fund and was knighted in 1986.
Margaret Callahan MD, PhD Medical Oncology Advisor
Margaret is a board-certified medical oncologist at the Memorial Sloan Kettering Cancer Center specializing in the use of immunotherapies to treat melanoma and other cancers. She is the Research Director of, Immunotherapeutics Program at the Immunotherapeutics Clinical Core, which is a specialized center for Phase 1 studies of new immunotherapy agents. As a laboratory member in the Ludwig Center at Memorial Sloan Kettering, she is involved in developing innovative approaches to monitoring patients treated with immunotherapy. She holds a BS in Molecular and Cell Biology from the University of Connecticut and an MD, PhD from the University of Connecticut School of Medicine. She completed her residency in Internal Medicine at the University of California, San Francisco, followed by a fellowship in clinical oncology at Memorial Sloan Kettering Cancer Center.
George Church PhD, Lead Scientific Advisor
Dr. Church is a pioneer of genome engineering, DNA sequencing, and synthetic biology. He has cofounded 24 biotechnology companies, authored over 500 papers and 140 patent publications. Dr. Church is a professor of genetics at Harvard Medical School and a professor of health sciences and technology at MIT and Harvard Medical School. He is the director of the Center for Genomically Engineered Organs (CGEO), the Harvard DOE Technology Center, the Lipper Center for Computational Genetics, and is a founding core member of the Wyss Institute for Biologically Inspired Engineering. Dr. Church is a member of the National Academy of Sciences (2011) and the National Academy of Engineering (2012) and has received the Franklin Institute’s Bower Award for Achievement in Science (2011). He holds a Ph.D. in biochemistry and molecular biology from Harvard University.
Susan Tannenbaum MD, Medical Oncology Advisor
Dr. Tannenbaum is Associate Professor of Medicine at the University of Connecticut Medical School and Chief, Division of Hematology/Oncology. Her clinical and research interests are focused on breast cancer care, from prevention, early detection, and treatment to survivorship. Her previous experience included nine years at the National Institutes of Health as a basic science researcher in endothelial cell biology and as a clinician for seven years in a busy private practice in Pasadena, California. She holds a BS from Cornell University and an MD from the State University of New York. Her post-graduate training was at the Bronx Municipal Hospital Center (Internal Medicine) and at the Hospital of the University of Pennsylvania (Hematology/ Oncology).